Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:33:34.461Z.
Calculation as of: 2026-10-06T16:33:34.461Z.
Quote observation: 2026-10-06T16:30:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1ca0602d484fef860d1886a06048f849113dfee726f77a026e2ec96edb2346c6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2015-05-11.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PRICE/FCF RATIO AVG TTM
N/A
PRICE/FCF RATIO AVG 3Y
N/A
PRICE/FCF RATIO AVG 5Y
N/A
PRICE/FCF RATIO AVG 10Y
N/A
PRICE/FCF RATIO AVG 15Y
N/A
PRICE/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$82.58M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$81.81M
Price/FCF Ratio
N/A
TTM Avg
786.60
3Y Avg
786.60
5Y Avg
786.60
Market Cap
$83.24M
Price/FCF Ratio
N/A
TTM Avg
17.74
3Y Avg
16.00
5Y Avg
17.53
Market Cap
$85.01M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MediciNova, Inc. (MNOV) | $82.45M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.58M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.72M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $82.05M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $81.81M | N/A | 786.60 | 786.60 | 786.60 |
| Cardiff Oncology, Inc. (CRDF)vs › | $83.24M | N/A | 17.74 | 16.00 | 17.53 |
| ProMIS Neurosciences, Inc. (PMN)vs › | $83.85M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.10M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | N/A | N/A | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $79.82M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2015-05-11 | 122.47 |
| 2015-05-08 | 121.26 |
| 2015-05-07 | 122.47 |
| 2015-05-06 | 124.59 |
| 2015-05-05 | 121.26 |
| 2015-05-04 | 119.44 |
| 2015-05-01 | 115.80 |
| 2015-04-30 | 117.62 |
| 2015-04-29 | 113.37 |
| 2015-04-28 | 116.41 |
| 2015-04-27 | 113.98 |
| 2015-04-24 | 123.98 |
| 2015-04-23 | 120.65 |
| 2015-04-22 | 120.04 |
| 2015-04-21 | 123.68 |
| 2015-04-20 | 123.68 |
| 2015-04-17 | 134.90 |
| 2015-04-16 | 150.36 |
| 2015-04-15 | 106.40 |
| 2015-04-14 | 105.19 |
| 2015-04-13 | 102.46 |
| 2015-04-10 | 105.19 |
| 2015-04-09 | 102.76 |
| 2015-04-08 | 105.31 |
| 2015-04-07 | 100.95 |
| 2015-04-06 | 103.07 |
| 2015-04-02 | 104.58 |
| 2015-04-01 | 107.61 |
| 2015-03-31 | 106.10 |
| 2015-03-30 | 108.83 |
| 2015-03-27 | 107.61 |
| 2015-03-26 | 100.64 |
| 2015-03-25 | 99.43 |
| 2015-03-24 | 103.37 |
| 2015-03-23 | 103.37 |
| 2015-03-20 | 107.01 |
| 2015-03-19 | 107.61 |
| 2015-03-18 | 103.67 |
| 2015-03-17 | 99.13 |
| 2015-03-16 | 98.52 |
| 2015-03-13 | 101.85 |
